These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18628519)

  • 1. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.
    Canonico M; Bouaziz E; Carcaillon L; Verstuyft C; Guiochon-Mantel A; Becquemont L; Scarabin PY;
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3082-7. PubMed ID: 18628519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
    Straczek C; Oger E; Yon de Jonage-Canonico MB; Plu-Bureau G; Conard J; Meyer G; Alhenc-Gelas M; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    Circulation; 2005 Nov; 112(22):3495-500. PubMed ID: 16301339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
    Canonico M; Oger E; Plu-Bureau G; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    Circulation; 2007 Feb; 115(7):840-5. PubMed ID: 17309934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women.
    Olié V; Plu-Bureau G; Conard J; Horellou MH; Canonico M; Scarabin PY
    Menopause; 2011 May; 18(5):488-93. PubMed ID: 21178641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
    Bouligand J; Cabaret O; Canonico M; Verstuyft C; Dubert L; Becquemont L; Guiochon-Mantel A; Scarabin PY;
    Clin Pharmacol Ther; 2011 Jan; 89(1):60-4. PubMed ID: 21107315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
    Scarabin PY; Oger E; Plu-Bureau G;
    Lancet; 2003 Aug; 362(9382):428-32. PubMed ID: 12927428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
    Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
    Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study.
    Canonico M; Oger E; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    J Thromb Haemost; 2006 Jun; 4(6):1259-65. PubMed ID: 16706969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
    Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
    Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone therapy and venous thromboembolism among postmenopausal women.
    Scarabin PY
    Front Horm Res; 2014; 43():21-32. PubMed ID: 24943295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
    Canonico M; Fournier A; Carcaillon L; Olié V; Plu-Bureau G; Oger E; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F; Scarabin PY
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):340-5. PubMed ID: 19834106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
    Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A;
    Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.
    Scarabin PY
    Climacteric; 2018 Aug; 21(4):341-345. PubMed ID: 29570359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormones and venous thromboembolism among postmenopausal women.
    Scarabin PY
    Climacteric; 2014 Dec; 17 Suppl 2():34-7. PubMed ID: 25223916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
    Canonico M
    Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.
    Jick H; Derby LE; Myers MW; Vasilakis C; Newton KM
    Lancet; 1996 Oct; 348(9033):981-3. PubMed ID: 8855853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.
    Hu M; Yang YL; Fok BS; Chan SW; Chu TT; Poon EW; Yin OQ; Lee VH; Tomlinson B
    Drug Metabol Drug Interact; 2012 Jan; 27(1):33-9. PubMed ID: 22718623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism.
    Renoux C; Dell'Aniello S; Brenner B; Suissa S
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):554-560. PubMed ID: 28326633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.